Metformin

An antidiabetic.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

2
Supporting references
0
Contradictory references
4
Clinical trials

General information

Metformin is a biguanide antidiabetic. It has antihyperglycemic properties and reduces LDL cholesterol and triglyceride levels (NCIt).

The TOGETHER trial data show that metformin does not reduce the rate of COVID-19-related hospitalization among high-risk patients. No other clinical benefit was observed either (Reis et al., 2022).

Metformin on PubChem
Metformin on DrugBank
Metformin on Wikipedia


Marketed as

ACTOPLUS MET; AVANDAMET; FORTAMET; GLUBRAVA; GLUCOPHAGE; GLUCOVANCE; GLUMETZA; GLYCON; INVOKAMET; JANUMET; JENTADUETO; KAZANO; KOMBIGLYZE; KOMBOGLYZE; QTERNMET; RIOMET; SEGLUROMET; SYNJARDY; TRIJARDY; VELMETIA; XIGDUO

Structure not available

CN(C)C(=N)N=C(N)N


Supporting references

Link Tested on Impact factor Notes Publication date DB entry date
Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19
Preprint
Patients

significantly associated with reduced mortality in women with obesity or type 2 diabetes hospitalized with COVID-19

Jun/20/2020 Jun/23/2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Small molecule
in silico 42.78 Apr/30/2020 Mar/30/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04604678 Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19 Not yet recruiting Phase 2 Feb/01/2021 Oct/01/2021
NCT04626089 Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2 Withdrawn Phase 2 Feb/01/2021 Feb/01/2021
NCT04510194 COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) Active, not recruiting Phase 3 Jan/01/2021 Feb/01/2023
NCT04625985 Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Completed Phase 2 Jul/14/2020 Mar/18/2021